These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 18535816)

  • 41. Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans.
    Anber V; Millar JS; McConnell M; Shepherd J; Packard CJ
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2507-14. PubMed ID: 9409221
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Turnover of 125I-VLDL and 131I-LDL apolipoprotein B in rabbits fed diets containing casein or soy protein.
    Khosla P; Samman S; Carroll KK; Huff MW
    Biochim Biophys Acta; 1989 Apr; 1002(2):157-63. PubMed ID: 2930765
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia.
    Chong T; Naples M; Federico L; Taylor D; Smith GJ; Cheung RC; Adeli K
    Atherosclerosis; 2006 Mar; 185(1):21-31. PubMed ID: 16002078
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Basal and insulin-regulated VLDL1 and VLDL2 kinetics in men with type 2 diabetes.
    Johansen RF; Søndergaard E; Sørensen LP; Jurik AG; Christiansen JS; Nielsen S
    Diabetologia; 2016 Apr; 59(4):833-43. PubMed ID: 26781548
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2589-600. PubMed ID: 9409231
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
    Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
    Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women.
    Campos H; Walsh BW; Judge H; Sacks FM
    J Clin Endocrinol Metab; 1997 Dec; 82(12):3955-63. PubMed ID: 9398695
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.
    Ballantyne CM; Raichlen JS; Cain VA
    J Am Coll Cardiol; 2008 Aug; 52(8):626-32. PubMed ID: 18702965
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
    Wolffenbuttel BH; Franken AA; Vincent HH;
    J Intern Med; 2005 Jun; 257(6):531-9. PubMed ID: 15910557
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low-density lipoprotein receptor binding determinants switch from apolipoprotein E to apolipoprotein B during conversion of hypertriglyceridemic very-low-density lipoprotein to low-density lipoproteins.
    Bradley WA; Hwang SL; Karlin JB; Lin AH; Prasad SC; Gotto AM; Gianturco SH
    J Biol Chem; 1984 Dec; 259(23):14728-35. PubMed ID: 6501314
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rosuvastatin Enhances the Catabolism of LDL apoB-100 in Subjects with Combined Hyperlipidemia in a Dose Dependent Manner.
    Le NA; Diffenderfer MR; Thongtang N; Ooi EM; Barrett PH; Horvath KV; Dolnikowski GG; Asztalos BF; Schaefer EJ; Brown WV
    Lipids; 2015 May; 50(5):447-58. PubMed ID: 25809021
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects.
    Demant T; Bedford D; Packard CJ; Shepherd J
    J Clin Invest; 1991 Nov; 88(5):1490-501. PubMed ID: 1939641
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
    Rosenson RS; Carlson DM; Kelly MT; Setze CM; Hirshberg B; Stolzenbach JC; Williams LA
    Cardiovasc Drugs Ther; 2011 Feb; 25(1):47-57. PubMed ID: 21174145
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.
    Dugani SB; Akinkuolie AO; Paynter N; Glynn RJ; Ridker PM; Mora S
    JAMA Cardiol; 2016 May; 1(2):136-45. PubMed ID: 27347563
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hyperapobetalipoproteinemia with compositional abnormality of LDL and IDL, a characteristic lipoprotein alteration in essential hypertension.
    Ryomoto KI; Suzuki M; Kanazawa A; Hasegawa M; Kimura Y; Yamamura T; Harano Y
    Am J Hypertens; 2000 Jun; 13(6 Pt 1):617-24. PubMed ID: 10912744
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Studies on the metabolism of apolipoprotein B in hypertriglyceridemic subjects using simultaneous administration of tritiated leucine and radioiodinated very low density lipoprotein.
    Beltz WF; Kesäniemi YA; Miller NH; Fisher WR; Grundy SM; Zech LA
    J Lipid Res; 1990 Mar; 31(3):361-74. PubMed ID: 2341804
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans.
    Reyes-Soffer G; Moon B; Hernandez-Ono A; Dionizovik-Dimanovski M; Jimenez J; Obunike J; Thomas T; Ngai C; Fontanez N; Donovan DS; Karmally W; Holleran S; Ramakrishnan R; Mittleman RS; Ginsberg HN
    Sci Transl Med; 2016 Jan; 8(323):323ra12. PubMed ID: 26819195
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Retrospective, observation study: Quantitative and qualitative effect of ezetimibe and HMG-CoA reductase inhibitors on LDL-cholesterol: are there disappearance thresholds for small, dense LDL and IDL?
    Inoue I; Awata T; Katayama S
    Recent Pat Cardiovasc Drug Discov; 2010 Jun; 5(2):143-52. PubMed ID: 20423317
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression.
    Vergès B; Duvillard L; Pais de Barros JP; Bouillet B; Baillot-Rudoni S; Rouland A; Petit JM; Degrace P; Demizieux L
    Diabetes Care; 2021 Apr; 44(4):1027-1037. PubMed ID: 33531418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.